Atypical Femoral XXXX and History of Bone-Specific Therapy, Concomitant Diseases, Medications, and Survival.

@entity1 @entity8 @entity3924 @entity174 @entity6 @entity1483 @entity6288 @entity5736 @entity173 @entity164 @entity65 @entity3330 @entity130
UNASSIGNED: Although @entity3330 ( @entity3330 ) are generally rare events; several studies have indicated a potential link between AFF and long-term bone-specific therapies (BSTs). The aim of this study was to analyze the frequency of AFF and potential associations with prior or ongoing BST. A total of 8851 Caucasian female and male @entity1 with de novo @entity173 treated in the largest Austrian level 1 @entity130 center from 2000 to 2013 were selected. Of the total, 194 @entity1 with a de novo low-traumatic subtrochanteric or shaft @entity174 were identified: 35 atypical and 159 typical @entity174 . Of these @entity1 , concomitant diseases, medication, previous @entity174 , and survival data were retrieved and analyzed. Female @entity1 in both groups were significantly older. The median survival was significantly shorter in @entity1 with AFF (9 vs 18  months; p  <  0.0001). @entity65 , @entity6288 , chronic @entity8 , @entity164 2 @entity6 , smoking (past or current history), and prevalent @entity174 were more frequent in AFF @entity1 , as well as the concomitant use of @entity3924 , @entity1483 , and @entity5736 . Although the number of @entity1 with current BST was less in (14.5%) both groups, more @entity1 in the AFF group were previously treated with BST (71% vs 49%; p  =  0.016), and they received these therapies for a longer time period. A combination of severe comorbidities, long-term pharmaceutical therapies, and a history of previous or ongoing BST was associated with an increased individual risk for AFF.
